Cited by

• In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units.

  Glupczynski Y, Huang TD, Berhin C, Claeys G, Delmée M, Ide L, Ieven G, Pierard D, Rodriguez-Villalobos H, Struelens M, Vaneldere J. Glupczynski Y, et al. Eur J Clin Microbiol Infect Dis. 2007 Nov;26(11):777-83. doi: 10.1007/s10096-007-0370-9. Eur J Clin Microbiol Infect Dis. 2007. PMID: 17668253
• Effectiveness of temocillin in treatment of non-urinary tract infections caused by ESBL-producing Enterobacterales and risk factors for failure.

  Mamona Kilu C, Menvielle C, Cataldi A, Hamon A, Duran C, Mwanba C, Tesmoingt C, Bouabdallah-Perrin L, Touche P, Chanh Hew Wai A, Ourghanlian C, Antignac M, Bildan MA, Bleibtreu A, Michelon H, Diamantis S, Pilmis B, Citerne A, Farfour E, Dinh A; Paris Temocillin study group. Mamona Kilu C, et al. JAC Antimicrob Resist. 2024 Oct 17;6(5):dlae164. doi: 10.1093/jacamr/dlae164. eCollection 2024 Oct. JAC Antimicrob Resist. 2024. PMID: 39421154 Free PMC article.
• Activity of temocillin against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae bloodstream isolates from a clinical trial.

  Stewart AG, Henderson A, Bauer MJ, Paterson DL, Harris PNA. Stewart AG, et al. JAC Antimicrob Resist. 2021 Dec 28;4(1):dlab192. doi: 10.1093/jacamr/dlab192. eCollection 2022 Mar. JAC Antimicrob Resist. 2021. PMID: 34988445 Free PMC article.
• Penicillins. A current review of their clinical pharmacology and therapeutic use.

  Nathwani D, Wood MJ. Nathwani D, et al. Drugs. 1993 Jun;45(6):866-894. doi: 10.2165/00003495-199345060-00002. Drugs. 1993. PMID: 7691496 Review.